{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+2+QD&page=2",
    "query": {
      "intervention": "Dose 2 QD",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+2+QD&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T12:59:50.796Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03900676",
      "title": "Efficacy and Safety Study of VB-1953 Topical Gel for Inflammatory Facial Acne Vulgaris",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "VB-1953 - 2%",
          "type": "DRUG"
        },
        {
          "name": "VB-1953 - 0% (Vehicle)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vyome Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "9 Years to 45 Years"
      },
      "enrollment_count": 480,
      "start_date": "2019-04-09",
      "completion_date": "2020-03",
      "has_results": false,
      "last_update_posted_date": "2019-10-01",
      "last_synced_at": "2026-09-26T12:59:50.796Z",
      "location_count": 12,
      "location_summary": "Ontario, California • Sherman Oaks, California • Brandon, Florida + 8 more",
      "locations": [
        {
          "city": "Ontario",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03900676"
    },
    {
      "nct_id": "NCT04765059",
      "title": "A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 98,
      "start_date": "2021-09-12",
      "completion_date": "2027-06-02",
      "has_results": true,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-09-26T12:59:50.796Z",
      "location_count": 2,
      "location_summary": "Silver Spring, Maryland • Boston, Massachusetts",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04765059"
    },
    {
      "nct_id": "NCT03535740",
      "title": "A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ALK-positive Advanced NSCLC"
      ],
      "interventions": [
        {
          "name": "Brigatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ariad Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2019-01-31",
      "completion_date": "2024-08-21",
      "has_results": true,
      "last_update_posted_date": "2025-07-31",
      "last_synced_at": "2026-09-26T12:59:50.796Z",
      "location_count": 10,
      "location_summary": "Orange, California • Whittier, California • Pueblo, Colorado + 7 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Pueblo",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03535740"
    },
    {
      "nct_id": "NCT03699774",
      "title": "Effect of Repeated Doses of DS-8500a on Pharmacokinetics of Rosuvastatin in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug Pharmacokinetics in Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "DS-8500a",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 24,
      "start_date": "2015-05-12",
      "completion_date": "2015-07-06",
      "has_results": false,
      "last_update_posted_date": "2019-02-12",
      "last_synced_at": "2026-09-26T12:59:50.796Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03699774"
    },
    {
      "nct_id": "NCT03449199",
      "title": "Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "TMX-049",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teijin America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2018-04-10",
      "completion_date": "2019-06-04",
      "has_results": true,
      "last_update_posted_date": "2022-08-30",
      "last_synced_at": "2026-09-26T12:59:50.796Z",
      "location_count": 55,
      "location_summary": "Flagstaff, Arizona • Mesa, Arizona • Alhambra, California + 41 more",
      "locations": [
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "Lomita",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03449199"
    },
    {
      "nct_id": "NCT07310901",
      "title": "A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obese But Otherwise Healthy Participants"
      ],
      "interventions": [
        {
          "name": "CRB-913",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corbus Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 252,
      "start_date": "2025-12-04",
      "completion_date": "2026-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-09-26T12:59:50.796Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Rancho Cucamonga, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Rancho Cucamonga",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Largo",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07310901"
    },
    {
      "nct_id": "NCT05236036",
      "title": "Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Astrocytoma",
        "Glioblastoma",
        "Glioblastoma, IDH-Wildtype",
        "MGMT-Unmethylated Glioblastoma",
        "Recurrent Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 86,
      "start_date": "2022-08-08",
      "completion_date": "2029-01-03",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-09-26T12:59:50.796Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Lake Forest, Illinois • Warrenville, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Lake Forest",
          "state": "Illinois"
        },
        {
          "city": "Warrenville",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05236036"
    },
    {
      "nct_id": "NCT00385307",
      "title": "Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "amibegron (SR58611A)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 680,
      "start_date": "2006-09",
      "completion_date": "2007-11",
      "has_results": false,
      "last_update_posted_date": "2009-03-25",
      "last_synced_at": "2026-09-26T12:59:50.796Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00385307"
    },
    {
      "nct_id": "NCT01277692",
      "title": "A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "GSK2336805 10mg",
          "type": "DRUG"
        },
        {
          "name": "GSK2336805 30mg",
          "type": "DRUG"
        },
        {
          "name": "GSK2236805 100mg",
          "type": "DRUG"
        },
        {
          "name": "GSK2236805 200mg",
          "type": "DRUG"
        },
        {
          "name": "GSK2236805 10mg",
          "type": "DRUG"
        },
        {
          "name": "GSK2236805 dose to be determined up to 100mg",
          "type": "DRUG"
        },
        {
          "name": "GSK2236805 5mg",
          "type": "DRUG"
        },
        {
          "name": "GSK2236805 30mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 58,
      "start_date": "2010-11-03",
      "completion_date": "2011-05-09",
      "has_results": false,
      "last_update_posted_date": "2017-06-28",
      "last_synced_at": "2026-09-26T12:59:50.796Z",
      "location_count": 3,
      "location_summary": "Chula Vista, California • Lenexa, Kansas • Willingboro, New Jersey",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Willingboro",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01277692"
    },
    {
      "nct_id": "NCT04930991",
      "title": "High Dose Omeprazole in Patients With Pancreatic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Exocrine Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Omeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 25,
      "start_date": "2021-09-07",
      "completion_date": "2026-04-03",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-09-26T12:59:50.796Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04930991"
    }
  ]
}